CLDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Celldex Therapeutics Inc (CLDX) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has positive developments in its clinical trials, the financial performance is weak, and the stock appears overbought based on technical indicators. Additionally, the lack of significant trading signals and mixed sentiment from options data suggest a cautious approach.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram of 0.807, indicating an upward trend. However, the RSI of 85.959 suggests the stock is overbought, and the price is near its resistance level of R2: 31.717, which may limit further short-term upside.
The company completed enrollment for its Chronic Spontaneous Urticaria clinical trial six months ahead of schedule, which led to an 18% surge in shares. This progress could be a long-term positive catalyst if the trial results are favorable.
The company reported a Q4 GAAP EPS of -$1.22, missing expectations by $0.20, and revenue declined by 89.8% YoY. Additionally, the stock has a 60% chance to decline by -2.25% in the next day and -5.1% in the next month based on historical patterns.
In Q4 2025, revenue dropped significantly by 89.70% YoY to $121,000. However, net income and EPS improved YoY, with net income increasing by 72.68% to -$81.32 million and EPS improving by 71.83% to -1.22. Gross margin remained steady at 100%. The financial performance indicates weak revenue growth but some improvement in cost management.
Barclays raised the price target to $24 from $21 but maintained an Equal Weight rating, reflecting a neutral stance on the stock.
